GRHL2

Across TCGA pan-cancer cohorts, GRHL2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GRHL2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where GRHL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GRHL2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where GRHL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRHL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+1.252	<.001	9	view →
LUAD	Female	II,III,IV	+0.634	<.001	8	view →
CCRCC	All	II,III,IV	−0.552	<.001	7	view →
HNSC	Female	All	−0.502	.001	7	view →
PDAC	Female	All	−0.344	.022	2	view →
COAD	All	All	+0.124	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GRHL2–LSCC

Open the LSCC breakdown →